Drug profile · INN
covid-19 vaccine (chadox1-s [recombinant])
VAXZEVRIA (PREVIOUSLY COVID-19 VACCINE ASTRAZENECA)
covid-19 vaccine (chadox1-s [recombinant]) (VAXZEVRIA (PREVIOUSLY COVID-19 VACCINE ASTRAZENECA)) is a spike glycoprotein vaccine antigen.
Drug details — covid-19 vaccine (chadox1-s [recombinant])
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
covid-19 vaccine (chadox1-s [recombinant]) (VAXZEVRIA (PREVIOUSLY COVID-19 VACCINE ASTRAZENECA)) is a spike glycoprotein vaccine antigen.
Key facts
Mechanism of action
Spike glycoprotein vaccine antigen
Primary target: Spike glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is covid-19 vaccine (chadox1-s [recombinant])?
covid-19 vaccine (chadox1-s [recombinant]) (VAXZEVRIA (PREVIOUSLY COVID-19 VACCINE ASTRAZENECA)) is a spike glycoprotein vaccine antigen.
What is the brand name for covid-19 vaccine (chadox1-s [recombinant])?
VAXZEVRIA (PREVIOUSLY COVID-19 VACCINE ASTRAZENECA) is a marketed brand name for covid-19 vaccine (chadox1-s [recombinant]). Check FDA Drugs@FDA for the current US label holder and prescribing information.